These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2598978)

  • 1. Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets.
    Al-Habet SM; Rogers HJ
    Eur J Clin Pharmacol; 1989; 37(4):423-6. PubMed ID: 2598978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of food and tablet formulation on plasma prednisolone levels following administration of enteric-coated tablets.
    Lee DA; Taylor GM; Walker JG; James VH
    Br J Clin Pharmacol; 1979 May; 7(5):523-8. PubMed ID: 475947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma prednisolone levels in man following administration in plain and enteric-coated forms.
    Wilson CG; May CS; Paterson JW
    Br J Clin Pharmacol; 1977 Jun; 4(3):351-5. PubMed ID: 901703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma prednisolone levels from enteric and non-enteric coated tablets estimated by an original technique.
    Morrison PJ; Bradbrook ID; Rogers HJ
    Br J Clin Pharmacol; 1977 Oct; 4(5):597-603. PubMed ID: 911606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetic and pharmacodynamic comparison of plain and enteric-coated prednisolone tablets.
    Adair CG; McCallion O; McElnay JC; Scott MG; Hamilton BA; McCann JP; Stanford CF; Nicholls DP
    Br J Clin Pharmacol; 1992 May; 33(5):495-9. PubMed ID: 1524961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption of enteric and non-enteric coated prednisolone tablets.
    Hulme B; James VH; Rault R
    Br J Clin Pharmacol; 1975 Aug; 2(4):317-20. PubMed ID: 1233990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and food impact assessment of ademetionine enteric-coated tablet as an endogenous substance drug in healthy Chinese volunteers.
    Zhang J; Liu H; Tang L; Lin H; Yao Y; Tong Y; Jin M; Wang K
    J Clin Pharm Ther; 2022 Jun; 47(6):738-744. PubMed ID: 34981547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability in absorption lag time of pyridoxal phosphate under fasting and pre- and post-meal conditions.
    Takahashi H; Ogata H; Nagai N; Sugito K; Shimamura H
    Biopharm Drug Dispos; 1994 Aug; 15(6):505-17. PubMed ID: 7993988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meal-dependent absorption of enteric-coated sodium valproate.
    Levy RH; Cenraud B; Loiseau P; Akbaraly R; Brachet-Liermain A; Guyot M; Gomeni R; Morselli PL
    Epilepsia; 1980 Jun; 21(3):273-80. PubMed ID: 6769666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in plasma prednisolone concentrations in renal transplant recipients given enteric-coated prednisolone.
    Henderson RG; Wheatley T; English J; Chakraborty J; Marks V
    Br Med J; 1979 Jun; 1(6177):1534-6. PubMed ID: 380747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption of quinidine from an enteric-coated preparation.
    Fremstad D; Nilsen OG; Amlie J; Storstein L; Olsson B; Jacobsen S
    Eur J Clin Pharmacol; 1979 Sep; 16(2):107-12. PubMed ID: 499306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enteric coated quinidine compared to sustained release preparations during repeated administration.
    Bakke OM; Aanderud L; Aslaksen A
    Acta Med Scand; 1980; 207(3):183-7. PubMed ID: 7368984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations.
    Latini R; Cerletti C; de Gaetano G; Dejana E; Galletti F; Urso R; Marzot M
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):313-8. PubMed ID: 3733281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of food on the absorption of acetylsalicylic acid from enteric-coated dosage forms.
    Bogentoft C; Carlsson I; Ekenved G; Magnusson A
    Eur J Clin Pharmacol; 1978 Dec; 14(5):351-5. PubMed ID: 32046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive treatment policies. A) Glucocorticoids: absorption of prednisolone. I. The effect of fasting, food, and food combined with antacids.
    Bergrem H; Djøseland O; Jervell J; Rugstad HE
    Scand J Urol Nephrol Suppl; 1981; 64():167-73. PubMed ID: 6959258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets.
    Pieniaszek HJ; Resetarits DE; Wilferth WW; Blumenthal HP; Bates TR
    J Clin Pharmacol; 1979 Jan; 19(1):39-45. PubMed ID: 33201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of omeprazole with enteric-coated salicylate tablets.
    Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy.
    Varum FJ; Hatton GB; Freire AC; Basit AW
    Eur J Pharm Biopharm; 2013 Aug; 84(3):573-7. PubMed ID: 23348235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.